nach oben

Breast Cancer Research and Treatment

Erschienen in:

30.08.2017 | Preclinical study

African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages

verfasst von: Cletus A. Arciero, Jing Yang, Limin Peng, Kevin C. Ward, Ruth O’Regan, Aysegul A. Sahin, Xiaoxian Li

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Racial disparity of breast cancer in each subtype and substage is not clear.

Methods

We reviewed 156,938 patients with breast cancer from 2010 to 2012 from the National Cancer Institute Surveillance, Epidemiology, and End Results database. Breast cancer was subtyped by hormone receptor (HR) and human epidermal growth factor 2 (HER2) status as HR+/HER2−, HR+/HER2+, HR−/HER2+, and HR−/HER2−.

Results

African American (AA) patients had worse overall survival (OS) and breast cancer cause-specific survival (BCSS) in HR+/HER2− stages III and IV breast cancer and HR−/HER2+ stage IV cancer; they had worse OS but not BCSS in HR+ /HER2− stage II cancer and HR−/HER2− stage II cancer.

Conclusion

AA patients with breast cancer had worse survival in certain subtype and stage, especially in ER+ breast cancer.

Whitman S, Orsi J, Hurlbert M (2012) The racial disparity in breast cancer mortality in the 25 largest cities in the United States. Cancer Epidemiol 36:e147–e151CrossRefPubMed

Newman LA, Griffith KA, Jatoi I et al (2006) Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol 24:1342–1349CrossRefPubMed

O’Brien KM, Cole SR, Tse CK et al (2010) Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 16:6100–6110CrossRefPubMedPubMedCentral

Menashe I, Anderson WF, Jatoi I et al (2009) Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis. J Natl Cancer Inst 101:993–1000CrossRefPubMedPubMedCentral

Schinkel JK, Zahm SH, Jatoi I et al (2014) Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data. Cancer Causes Control 25:959–968CrossRefPubMed

Adams SA, Butler WM, Fulton J et al (2012) Racial disparities in breast cancer mortality in a multiethnic cohort in the Southeast. Cancer 118:2693–2699CrossRefPubMed

Warner ET, Tamimi RM, Hughes ME et al (2012) Time to diagnosis and breast cancer stage by race/ethnicity. Breast Cancer Res Treat 136:813–821CrossRefPubMedPubMedCentral

Warner ET, Tamimi RM, Hughes ME et al (2015) Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors. J Clin Oncol 33:2254–2261CrossRefPubMedPubMedCentral

Iqbal J, Ginsburg O, Rochon PA et al (2015) Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA 313:165–173CrossRefPubMed

10.

Mortel M, Rauscher GH, Murphy AM et al (2015) Racial and ethnic disparity in symptomatic breast cancer awareness despite a recent screen: the role of tumor biology and mammography facility characteristics. Cancer Epidemiol Biomark Prev 24:1599–1606CrossRef

11.

Sparano JA, Wang M, Zhao F et al (2012) Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst 104:406–414CrossRefPubMedPubMedCentral

12.

Roseland ME, Pressler ME, Lamerato LE et al (2015) Racial differences in breast cancer survival in a large urban integrated health system. Cancer 121:3668–3675CrossRefPubMed

13.

Nurgalieva ZZ, Franzini L, Morgan R et al (2013) Surveillance mammography use after treatment of primary breast cancer and racial disparities in survival. Med Oncol 30:691CrossRefPubMed

14.

Dave B, Gonzalez DD, Liu ZB et al (2017) Role of RPL39 in metaplastic breast cancer. J Natl Cancer Inst 109

15.

Krishnamurti U, Wetherilt CS, Yang J et al (2017) Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers. Hum Pathol 64:7–12CrossRefPubMed

16.

Li X, Oprea-Ilies GM, Krishnamurti U (2017) New developments in breast cancer and their impact on daily practice in pathology. Arch Pathol Lab Med 141:490–498CrossRefPubMed

17.

Li X, Wei B, Sonmez C et al (2017) High tumor budding count is associated with adverse clinicopathologic features and poor prognosis in breast carcinoma. Hum Pathol

18.

Li X, Wetherilt CS, Krishnamurti U et al (2016) Stromal PD-L1 expression is associated with better disease-free survival in triple-negative breast cancer. Am J Clin Pathol 146:496–502CrossRefPubMed

19.

Li X, Yang J, Krishnamurti U et al (2017) Hormone receptor-positive breast cancer has a worse prognosis in male than in female patients. Clin Breast Cancer 17:356–366CrossRefPubMed

20.

Li X, Yang J, Peng L et al (2017) Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat 161:279–287CrossRefPubMed

21.

Li XB, Krishnamurti U, Bhattarai S et al (2016) Biomarkers predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer. Am J Clin Pathol 145:871–878CrossRefPubMed

22.

Ogden A, Garlapati C, Li XB et al (2017) Multi-institutional study of nuclear KIFC1 as a biomarker of poor prognosis in African American women with triple-negative breast cancer. Sci Rep 7:42289CrossRefPubMedPubMedCentral

23.

Pannu V, Mittal K, Cantuaria G et al (2015) Rampant centrosome amplification underlies more aggressive disease course of triple negative breast cancers. Oncotarget 6:10487–10497CrossRefPubMedPubMedCentral

24.

Wright N, Rida P, Krishnamurti U et al (2017) Targeted drugs and diagnostic assays: companions in the race to combat ethnic disparity. Front Biosci (Landmark Ed) 22:193–211CrossRef

25.

Wright N, Xia J, Cantuaria G et al (2017) Distinctions in breast tumor recurrence patterns post-therapy among racially distinct populations. PLoS ONE 12:e0170095CrossRefPubMedPubMedCentral

26.

Zelnak AB, Nikolinakos P, Srinivasiah J et al (2015) High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy. Clin Breast Cancer 15:31–36CrossRefPubMed

27.

Lund MJ, Trivers KF, Porter PL et al (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 113:357–370CrossRefPubMed

28.

Dawood S, Broglio K, Kau SW et al (2009) Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 27:220–226CrossRefPubMedPubMedCentral

29.

Chu KC, Lamar CA, Freeman HP (2003) Racial disparities in breast carcinoma survival rates: separating factors that affect diagnosis from factors that affect treatment. Cancer 97:2853–2860CrossRefPubMed

30.

Ma H, Lu Y, Malone KE et al (2013) Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status. BMC Cancer 13:1–11CrossRef

31.

Gleason MX, Mdzinarishvili T, Sherman S (2012) Breast cancer incidence in black and white women stratified by estrogen and progesterone receptor statuses. PLoS ONE 7:e49359CrossRefPubMedPubMedCentral

32.

Wright JL, Reis IM, Zhao W et al (2012) Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy. Breast 21:276–283CrossRefPubMed

33.

Vaz-Luis I, Lin NU, Keating NL et al (2015) Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. Breast Cancer Res Treat 151:697–707CrossRefPubMed

34.

Tichy JR, Deal AM, Anders CK et al (2015) Race, response to chemotherapy, and outcome within clinical breast cancer subtypes. Breast Cancer Res Treat 150:667–674CrossRefPubMedPubMedCentral

35.

EBCTCG (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386:1341–1352CrossRef

36.

EBCTCG (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–784CrossRef

37.

Fisher B, Jeong J-H, Bryant J et al (2004) Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National surgical adjuvant breast and bowel project randomised clinical trials. Lancet 364:858–868CrossRefPubMed

38.

Friese CR, Pini TM, Li Y et al (2013) Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat 138:931–939CrossRefPubMedPubMedCentral

39.

Neugut AI, Subar M, Wilde ET et al (2011) Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 29:2534–2542CrossRefPubMedPubMedCentral

40.

Roberts MC, Wheeler SB, Reeder-Hayes K (2015) Racial/ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review. Am J of Public Health 105:e4–e15CrossRef

41.

Ma H, Lu Y, Marchbanks PA et al (2013) Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women. Breast Cancer Res 15:1–12CrossRef

42.

Reding KW, Chen C, Lowe K et al (2012) Estrogen-related genes and their contribution to racial differences in breast cancer risk. Cancer Causes Control 23:671–681CrossRefPubMedPubMedCentral

Titel: African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages
verfasst von: Cletus A. Arciero
Jing Yang
Limin Peng
Kevin C. Ward
Ruth O’Regan
Aysegul A. Sahin
Xiaoxian Li
Publikationsdatum: 30.08.2017
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2017
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4484-1

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages